<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nichols, Emma Hitt</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Axelsson, Anna</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Losartan Lacks Benefit in Inherited HCM</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">18-19</style></pages><abstract><style  face="normal" font="default" size="100%">Hypertrophic cardiomyopathy (HCM) has a prevalence of 1 in every 500 individuals, making it the most frequently inherited cardiomyopathy, and it results in the fibrosis and hypertrophy of the left ventricle. This article discusses data from the Inhibition of the Renin Angiotensin System With Losartan in Patients With Hypertrophic Cardiomyopathy [INHERIT; NCT01447654] trial, which investigated the use of losartan for HCM.</style></abstract><number><style face="normal" font="default" size="100%">52</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>